Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 27, 2026

Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform

View original at finance.yahoo.com
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform Combined with the anticipated sale of the BTC and Receivable collections, Datavault AI projects $200M+ infusion of cash without equity di…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Quantum-Ready Edge Network has aggregate annual revenue potential of $10 billion to $100 billion

    60% confidence
  • Datavault AI has previously secured and in stock Nvidia GPUs with a current market value of $1.2 billion that will enable the nationwide rollout

    60% confidence
  • Combined with the anticipated sale of the BTC and Receivable collections, Datavault AI projects $200M+ infusion of cash without equity dilution

    60% confidence
  • Scilex will receive 30% of all gross network revenues until aggregate payments reach $250M (Interim Cap), then 15% until aggregate payments reach $1.2B (Additional Cap), then 5% of network revenues thereafter

    60% confidence
  • The $120 million cash contribution will be used to fund the deployment of Datavault AI's quantum-ready edge network, including build-out, equipment, related working capital, and reasonable overhead expenses directly attributable thereto

    60% confidence

Data points we hold from this source

Datavault AI Inc. · revenue10000000000 USD
Datavault AI Inc. · cash200000000 USD
Datavault AI Inc. · market cap1200000000 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com